EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Management of Mycobacterium ulcerans infection (Buruli ulcer) in Australia: consensus statement

Stephen Muhi, Victoria Rv Cox, Matthew O'Brien, Jonathan T Priestley, Jodie Hill, Adrian Murrie, Anthony McDonald, Peter Callan, Grant A Jenkin, N Deborah Friedman, Kasha P Singh iD, Callum Maggs und 4 weitere

Medical Journal of Australia · 2025

DOI: 10.5694/mja2.52591 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medical Journal of Australia, 2025. Verfasst von Stephen Muhi und 15 weiteren Autor:innen. Beteiligte Einrichtung: Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC. Hauptthemen laut MEDLINE: Buruli Ulcer, Mycobacterium ulcerans, Anti-Bacterial Agents. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction Buruli ulcer, caused by Mycobacterium ulcerans , is increasing in incidence and spreading to new areas in southeast Australia. With increasing experience and emerging evidence, this consensus statement considers contemporary data to provide up‐to‐date recommendations to clinicians who may encounter this disease. The emergence of Buruli ulcer in previously non‐endemic areas highlights the importance of increasing clinician and community awareness of this disease. Main recommendations and changes in management as a result of this consensus statement: Buruli ulcer is a notifiable disease in Victoria, the Northern Territory and Queensland. Cases identified in other states or territories should be discussed with relevant health authorities. We call for Buruli ulcer to be made nationally notifiable to monitor for its potential emergence in non‐endemic regions. Diagnosis using polymerase chain reaction is sensitive and specific if performed correctly; a dry swab under the undermined edge of ulcers or a tissue sample via punch biopsy if the lesion is not ulcerated is recommended. If swabs are incorrectly performed or performed on non‐ulcerated skin, they can give a false negative result. There is high quality evidence to support treatment of eight weeks’ duration using rifampicin‐based dual oral antibiotic therapy, in combination with clarithromycin or a fluoroquinolone; relapse is very rare but can occur in people with risk factors. There is emerging evidence for shorter durations of treatment (six weeks) in individuals with small lesions who are at low risk of relapse and in those who have undergone surgical excision of the lesion (four weeks). Patients should be warned that ulcers typically enlarge with antibiotic treatment, will not have healed by completion of antibiotics, and take a median of four to five months to heal. Surgical management is usually not required, but may be beneficial to reduce healing times, avoid or reduce the duration of antibiotics, and manage paradoxical reactions. Early identification and treatment of paradoxical reactions is important, as they are associated with increased tissue necrosis and delayed wound healing. Good wound care is critical in successful treatment of Buruli ulcer, as it enhances healing and prevents secondary bacterial infection. Compared with adults, children have a higher proportion of non‐ulcerative and severe lesions, are less likely to experience adverse antibiotic effects, but have higher rates of paradoxical reactions; specialist referral is recommended.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Buruli UlcerMycobacterium ulceransAnti-Bacterial AgentsHumansAustraliaRifampin

Stichwörter der Autor:innen

Mycobacterium

Substanzen

Anti-Bacterial AgentsRifampin

Autor:innen und Institutionen

  • Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC.
  • Victorian Infectious Diseases Service, Royal Melbourne Hospital, Melbourne, VIC.
  • Menzies School of Health Research, Darwin, NT.
  • Monash Children's Hospital, Melbourne, VIC.
  • South Coast Medical, Blairgowrie, VIC.
  • Sorrento Medical Centre, Sorrento, VIC.

ORCID-Profile: Kasha P Singh, Paul Dr Johnson

Zitieren

APA

Muhi, S., Cox, V. R., O'Brien, M., Priestley, J. T., Hill, J., Murrie, A., McDonald, A., Callan, P., Jenkin, G. A., Friedman, N. D., Singh, K. P., Maggs, C., Kelley, P., Athan, E., Johnson, P. D., & O'Brien, D. P. (2025). Management of Mycobacterium ulcerans infection (Buruli ulcer) in Australia: consensus statement. Medical Journal of Australia. https://doi.org/10.5694/mja2.52591

Vancouver

Muhi S, Cox VR, O'Brien M, Priestley JT, Hill J, Murrie A, et al. Management of Mycobacterium ulcerans infection (Buruli ulcer) in Australia: consensus statement. Medical Journal of Australia. 2025. doi:10.5694/mja2.52591

BibTeX
@article{Muhi2025,
  author = {Muhi, Stephen and Cox, Victoria Rv and O'Brien, Matthew and Priestley, Jonathan T and Hill, Jodie and Murrie, Adrian and McDonald, Anthony and Callan, Peter and Jenkin, Grant A and Friedman, N Deborah and Singh, Kasha P and Maggs, Callum and Kelley, Peter and Athan, Eugene and Johnson, Paul Dr and O'Brien, Daniel P},
  title = {Management of Mycobacterium ulcerans infection (Buruli ulcer) in Australia: consensus statement},
  journal = {Medical Journal of Australia},
  year = {2025},
  doi = {10.5694/mja2.52591}
}
Kostenlos starten →